- Bioactive Compounds
- By Signaling Pathways
- PI3K/Akt/mTOR
- Epigenetics
- Methylation
- Immunology & Inflammation
- Protein Tyrosine Kinase
- Angiogenesis
- Apoptosis
- Autophagy
- ER stress & UPR
- JAK/STAT
- MAPK
- Cytoskeletal Signaling
- Cell Cycle
- TGF-beta/Smad
- DNA Damage/DNA Repair
- Compound Libraries
- Antibodies
- Bioreagents
- qPCR
- 2x SYBR Green qPCR Master Mix
- 2x SYBR Green qPCR Master Mix(Low ROX)
- 2x SYBR Green qPCR Master Mix(High ROX)
- Protein Assay
- Protein A/G Magnetic Beads for IP
- Anti-Flag magnetic beads
- Anti-Flag Affinity Gel
- Anti-Myc magnetic beads
- Anti-HA magnetic beads
- Magnetic Separator
- Poly DYKDDDDK Tag Peptide lyophilized powder
- Protease Inhibitor Cocktail
- Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO)
- Phosphatase Inhibitor Cocktail (2 Tubes, 100X)
- Cell Biology
- Cell Counting Kit-8 (CCK-8)
- Animal Experiment
- Mouse Direct PCR Kit (For Genotyping)
- New Products
- Contact Us
-
Australia
-
Austria
-
Belgium
-
Canada
-
China
-
Czech Republic
-
Denmark
-
Finland
-
France
-
Germany
-
Greece
-
Hong Kong
-
Hungary
-
Iceland
-
India
-
Ireland
-
Israel
-
Italy
-
Japan
-
Korea
-
Luxembourg
-
Malaysia
-
Netherlands
-
New Zealand
-
Norway
-
Poland
-
Qatar
-
Romania
-
Saudi Arabia
-
Singapore
-
Spain
-
Sweden
-
Switzerland
-
Taiwan
-
Turkey
-
United Kingdom
-
United States
-
Other Countries
BAY-61-3606
BAY-61-3606 is a potent and selective inhibitor of Syk kinase (Ki = 7.5 nM). BAY-61-3606 induces cell cycle arrest and apoptosis.
BAY-61-3606 Chemical Structure
CAS No. 648903-57-5
Purity & Quality Control
Batch:
Purity:
99.80%
99.80
BAY-61-3606 Related Products
| Related Targets | ZAP70 | Click to Expand |
|---|---|---|
| Related Products | R406 R406 (free base) PRT062607 (P505-15) HCl Entospletinib (GS-9973) Piceatannol PRT-060318 2HCl TAK-659 Hydrochloride RO9021 | Click to Expand |
| Related Compound Libraries | Tyrosine Kinase Inhibitor Library PI3K/Akt Inhibitor Library Angiogenesis Related compound Library HIF-1 Signaling Pathway Compound Library FDA-approved Anticancer Drug Library | Click to Expand |
Signaling Pathway
Cell Data
| Cell Lines | Assay Type | Concentration | Incubation Time | Formulation | Activity Description | PMID |
|---|---|---|---|---|---|---|
| MV-4-11 | Growth inhibition assay | Inhibition of human MV-4-11 cell growth in a cell viability assay, IC50=0.007394μM | SANGER | |||
| EoL-1-cell | Growth inhibition assay | Inhibition of human EoL-1-cell cell growth in a cell viability assay, IC50=0.33275μM | SANGER | |||
| NALM-6 | Growth inhibition assay | Inhibition of human NALM-6 cell growth in a cell viability assay, IC50=0.41739μM | SANGER | |||
| P30-OHK | Growth inhibition assay | Inhibition of human P30-OHK cell growth in a cell viability assay, IC50=0.42687μM | SANGER | |||
| NOS-1 | Growth inhibition assay | Inhibition of human NOS-1 cell growth in a cell viability assay, IC50=0.4813μM | SANGER | |||
| CAL-12T | Growth inhibition assay | Inhibition of human CAL-12T cell growth in a cell viability assay, IC50=0.49562μM | SANGER | |||
| TE-12 | Growth inhibition assay | Inhibition of human TE-12 cell growth in a cell viability assay, IC50=0.53123μM | SANGER | |||
| SR | Growth inhibition assay | Inhibition of human SR cell growth in a cell viability assay, IC50=0.5481μM | SANGER | |||
| ALL-PO | Growth inhibition assay | Inhibition of human ALL-PO cell growth in a cell viability assay, IC50=0.5572μM | SANGER | |||
| LCLC-97TM1 | Growth inhibition assay | Inhibition of human LCLC-97TM1 cell growth in a cell viability assay, IC50=0.56966μM | SANGER | |||
| MOLT-16 | Growth inhibition assay | Inhibition of human MOLT-16 cell growth in a cell viability assay, IC50=0.57077μM | SANGER | |||
| ST486 | Growth inhibition assay | Inhibition of human ST486 cell growth in a cell viability assay, IC50=0.57618μM | SANGER | |||
| QIMR-WIL | Growth inhibition assay | Inhibition of human QIMR-WIL cell growth in a cell viability assay, IC50=0.5818μM | SANGER | |||
| 697 | Growth inhibition assay | Inhibition of human 697 cell growth in a cell viability assay, IC50=0.58188μM | SANGER | |||
| Daudi | Growth inhibition assay | Inhibition of human Daudi cell growth in a cell viability assay, IC50=0.60699μM | SANGER | |||
| HMV-II | Growth inhibition assay | Inhibition of human HMV-II cell growth in a cell viability assay, IC50=0.66443μM | SANGER | |||
| BL-70 | Growth inhibition assay | Inhibition of human BL-70 cell growth in a cell viability assay, IC50=0.67074μM | SANGER | |||
| CMK | Growth inhibition assay | Inhibition of human CMK cell growth in a cell viability assay, IC50=0.68171μM | SANGER | |||
| GDM-1 | Growth inhibition assay | Inhibition of human GDM-1 cell growth in a cell viability assay, IC50=0.68279μM | SANGER | |||
| NCI-H358 | Growth inhibition assay | Inhibition of human NCI-H358 cell growth in a cell viability assay, IC50=0.68943μM | SANGER | |||
| RPMI-2650 | Growth inhibition assay | Inhibition of human RPMI-2650 cell growth in a cell viability assay, IC50=0.69635μM | SANGER | |||
| A3-KAW | Growth inhibition assay | Inhibition of human A3-KAW cell growth in a cell viability assay, IC50=0.73961μM | SANGER | |||
| LB1047-RCC | Growth inhibition assay | Inhibition of human LB1047-RCC cell growth in a cell viability assay, IC50=0.74125μM | SANGER | |||
| HC-1 | Growth inhibition assay | Inhibition of human HC-1 cell growth in a cell viability assay, IC50=0.75399μM | SANGER | |||
| SW982 | Growth inhibition assay | Inhibition of human SW982 cell growth in a cell viability assay, IC50=0.77461μM | SANGER | |||
| GCT | Growth inhibition assay | Inhibition of human GCT cell growth in a cell viability assay, IC50=0.79887μM | SANGER | |||
| KE-37 | Growth inhibition assay | Inhibition of human KE-37 cell growth in a cell viability assay, IC50=0.83527μM | SANGER | |||
| EB2 | Growth inhibition assay | Inhibition of human EB2 cell growth in a cell viability assay, IC50=0.83703μM | SANGER | |||
| SIG-M5 | Growth inhibition assay | Inhibition of human SIG-M5 cell growth in a cell viability assay, IC50=0.84816μM | SANGER | |||
| PSN1 | Growth inhibition assay | Inhibition of human PSN1 cell growth in a cell viability assay, IC50=0.89708μM | SANGER | |||
| MES-SA | Growth inhibition assay | Inhibition of human MES-SA cell growth in a cell viability assay, IC50=0.95991μM | SANGER | |||
| MONO-MAC-6 | Growth inhibition assay | Inhibition of human MONO-MAC-6 cell growth in a cell viability assay, IC50=0.9631μM | SANGER | |||
| 769-P | Growth inhibition assay | Inhibition of human 769-P cell growth in a cell viability assay, IC50=0.98008μM | SANGER | |||
| MLMA | Growth inhibition assay | Inhibition of human MLMA cell growth in a cell viability assay, IC50=0.99318μM | SANGER | |||
| PA-1 | Growth inhibition assay | Inhibition of human PA-1 cell growth in a cell viability assay, IC50=1.00916μM | SANGER | |||
| LB831-BLC | Growth inhibition assay | Inhibition of human LB831-BLC cell growth in a cell viability assay, IC50=1.02039μM | SANGER | |||
| U-698-M | Growth inhibition assay | Inhibition of human U-698-M cell growth in a cell viability assay, IC50=1.02151μM | SANGER | |||
| NKM-1 | Growth inhibition assay | Inhibition of human NKM-1 cell growth in a cell viability assay, IC50=1.057μM | SANGER | |||
| DoTc2-4510 | Growth inhibition assay | Inhibition of human DoTc2-4510 cell growth in a cell viability assay, IC50=1.06452μM | SANGER | |||
| BC-1 | Growth inhibition assay | Inhibition of human BC-1 cell growth in a cell viability assay, IC50=1.06801μM | SANGER | |||
| IST-SL2 | Growth inhibition assay | Inhibition of human IST-SL2 cell growth in a cell viability assay, IC50=1.07117μM | SANGER | |||
| CA46 | Growth inhibition assay | Inhibition of human CA46 cell growth in a cell viability assay, IC50=1.0829μM | SANGER | |||
| ES7 | Growth inhibition assay | Inhibition of human ES7 cell growth in a cell viability assay, IC50=1.08755μM | SANGER | |||
| COR-L105 | Growth inhibition assay | Inhibition of human COR-L105 cell growth in a cell viability assay, IC50=1.13754μM | SANGER | |||
| MC-CAR | Growth inhibition assay | Inhibition of human MC-CAR cell growth in a cell viability assay, IC50=1.14296μM | SANGER | |||
| MCF7 | Growth inhibition assay | Inhibition of human MCF7 cell growth in a cell viability assay, IC50=1.14784μM | SANGER | |||
| OS-RC-2 | Growth inhibition assay | Inhibition of human OS-RC-2 cell growth in a cell viability assay, IC50=1.16958μM | SANGER | |||
| EW-1 | Growth inhibition assay | Inhibition of human EW-1 cell growth in a cell viability assay, IC50=1.17046μM | SANGER | |||
| SW872 | Growth inhibition assay | Inhibition of human SW872 cell growth in a cell viability assay, IC50=1.17605μM | SANGER | |||
| RS4-11 | Growth inhibition assay | Inhibition of human RS4-11 cell growth in a cell viability assay, IC50=1.23459μM | SANGER | |||
| ES4 | Growth inhibition assay | Inhibition of human ES4 cell growth in a cell viability assay, IC50=1.23968μM | SANGER | |||
| ES6 | Growth inhibition assay | Inhibition of human ES6 cell growth in a cell viability assay, IC50=1.24166μM | SANGER | |||
| A375 | Growth inhibition assay | Inhibition of human A375 cell growth in a cell viability assay, IC50=1.26823μM | SANGER | |||
| TE-15 | Growth inhibition assay | Inhibition of human TE-15 cell growth in a cell viability assay, IC50=1.28242μM | SANGER | |||
| NCI-H2122 | Growth inhibition assay | Inhibition of human NCI-H2122 cell growth in a cell viability assay, IC50=1.2826μM | SANGER | |||
| HEL | Growth inhibition assay | Inhibition of human HEL cell growth in a cell viability assay, IC50=1.3458μM | SANGER | |||
| 786-0 | Growth inhibition assay | Inhibition of human 786-0 cell growth in a cell viability assay, IC50=1.36048μM | SANGER | |||
| ACHN | Growth inhibition assay | Inhibition of human ACHN cell growth in a cell viability assay, IC50=1.37828μM | SANGER | |||
| WSU-NHL | Growth inhibition assay | Inhibition of human WSU-NHL cell growth in a cell viability assay, IC50=1.38488μM | SANGER | |||
| BL-41 | Growth inhibition assay | Inhibition of human BL-41 cell growth in a cell viability assay, IC50=1.39383μM | SANGER | |||
| 639-V | Growth inhibition assay | Inhibition of human 639-V cell growth in a cell viability assay, IC50=1.42777μM | SANGER | |||
| RPMI-6666 | Growth inhibition assay | Inhibition of human RPMI-6666 cell growth in a cell viability assay, IC50=1.4389μM | SANGER | |||
| CESS | Growth inhibition assay | Inhibition of human CESS cell growth in a cell viability assay, IC50=1.44695μM | SANGER | |||
| KYSE-270 | Growth inhibition assay | Inhibition of human KYSE-270 cell growth in a cell viability assay, IC50=1.45003μM | SANGER | |||
| EW-13 | Growth inhibition assay | Inhibition of human EW-13 cell growth in a cell viability assay, IC50=1.47333μM | SANGER | |||
| CTV-1 | Growth inhibition assay | Inhibition of human CTV-1 cell growth in a cell viability assay, IC50=1.49631μM | SANGER | |||
| J82 | Growth inhibition assay | Inhibition of human J82 cell growth in a cell viability assay, IC50=1.51287μM | SANGER | |||
| A2780 | Growth inhibition assay | Inhibition of human A2780 cell growth in a cell viability assay, IC50=1.52548μM | SANGER | |||
| KGN | Growth inhibition assay | Inhibition of human KGN cell growth in a cell viability assay, IC50=1.54262μM | SANGER | |||
| JiyoyeP-2003 | Growth inhibition assay | Inhibition of human JiyoyeP-2003 cell growth in a cell viability assay, IC50=1.55496μM | SANGER | |||
| SW1710 | Growth inhibition assay | Inhibition of human SW1710 cell growth in a cell viability assay, IC50=1.65755μM | SANGER | |||
| MPP-89 | Growth inhibition assay | Inhibition of human MPP-89 cell growth in a cell viability assay, IC50=1.67329μM | SANGER | |||
| EW-16 | Growth inhibition assay | Inhibition of human EW-16 cell growth in a cell viability assay, IC50=1.68039μM | SANGER | |||
| LB996-RCC | Growth inhibition assay | Inhibition of human LB996-RCC cell growth in a cell viability assay, IC50=1.70322μM | SANGER | |||
| NB1 | Growth inhibition assay | Inhibition of human NB1 cell growth in a cell viability assay, IC50=1.71217μM | SANGER | |||
| A431 | Growth inhibition assay | Inhibition of human A431 cell growth in a cell viability assay, IC50=1.73227μM | SANGER | |||
| HOP-62 | Growth inhibition assay | Inhibition of human HOP-62 cell growth in a cell viability assay, IC50=1.74542μM | SANGER | |||
| TE-10 | Growth inhibition assay | Inhibition of human TE-10 cell growth in a cell viability assay, IC50=1.75604μM | SANGER | |||
| RPMI-8402 | Growth inhibition assay | Inhibition of human RPMI-8402 cell growth in a cell viability assay, IC50=1.76703μM | SANGER | |||
| 8505C | Growth inhibition assay | Inhibition of human 8505C cell growth in a cell viability assay, IC50=1.77046μM | SANGER | |||
| NCI-H1437 | Growth inhibition assay | Inhibition of human NCI-H1437 cell growth in a cell viability assay, IC50=1.79695μM | SANGER | |||
| A4-Fuk | Growth inhibition assay | Inhibition of human A4-Fuk cell growth in a cell viability assay, IC50=1.8079μM | SANGER | |||
| HUTU-80 | Growth inhibition assay | Inhibition of human HUTU-80 cell growth in a cell viability assay, IC50=1.81156μM | SANGER | |||
| SK-MES-1 | Growth inhibition assay | Inhibition of human SK-MES-1 cell growth in a cell viability assay, IC50=1.81241μM | SANGER | |||
| NCI-H2342 | Growth inhibition assay | Inhibition of human NCI-H2342 cell growth in a cell viability assay, IC50=1.81533μM | SANGER | |||
| LC-2-ad | Growth inhibition assay | Inhibition of human LC-2-ad cell growth in a cell viability assay, IC50=1.82238μM | SANGER | |||
| SK-HEP-1 | Growth inhibition assay | Inhibition of human SK-HEP-1 cell growth in a cell viability assay, IC50=1.82407μM | SANGER | |||
| SNU-C2B | Growth inhibition assay | Inhibition of human SNU-C2B cell growth in a cell viability assay, IC50=1.83912μM | SANGER | |||
| SK-MEL-2 | Growth inhibition assay | Inhibition of human SK-MEL-2 cell growth in a cell viability assay, IC50=1.89372μM | SANGER | |||
| KARPAS-45 | Growth inhibition assay | Inhibition of human KARPAS-45 cell growth in a cell viability assay, IC50=1.90137μM | SANGER | |||
| HCC70 | Growth inhibition assay | Inhibition of human HCC70 cell growth in a cell viability assay, IC50=1.92994μM | SANGER | |||
| NTERA-S-cl-D1 | Growth inhibition assay | Inhibition of human NTERA-S-cl-D1 cell growth in a cell viability assay, IC50=1.96493μM | SANGER | |||
| EW-7 | Growth inhibition assay | Inhibition of human EW-7 cell growth in a cell viability assay, IC50=1.97791μM | SANGER | |||
| KMOE-2 | Growth inhibition assay | Inhibition of human KMOE-2 cell growth in a cell viability assay, IC50=1.97917μM | SANGER | |||
| CCRF-CEM | Growth inhibition assay | Inhibition of human CCRF-CEM cell growth in a cell viability assay, IC50=1.98173μM | SANGER | |||
| BPH-1 | Growth inhibition assay | Inhibition of human BPH-1 cell growth in a cell viability assay, IC50=1.99092μM | SANGER | |||
| NCI-SNU-1 | Growth inhibition assay | Inhibition of human NCI-SNU-1 cell growth in a cell viability assay, IC50=1.99098μM | SANGER | |||
| SK-LU-1 | Growth inhibition assay | Inhibition of human SK-LU-1 cell growth in a cell viability assay, IC50=2.02757μM | SANGER | |||
| DOHH-2 | Growth inhibition assay | Inhibition of human DOHH-2 cell growth in a cell viability assay, IC50=2.03195μM | SANGER | |||
| EFO-27 | Growth inhibition assay | Inhibition of human EFO-27 cell growth in a cell viability assay, IC50=2.0598μM | SANGER | |||
| SUP-T1 | Growth inhibition assay | Inhibition of human SUP-T1 cell growth in a cell viability assay, IC50=2.09626μM | SANGER | |||
| NCI-H64 | Growth inhibition assay | Inhibition of human NCI-H64 cell growth in a cell viability assay, IC50=2.16011μM | SANGER | |||
| DU-4475 | Growth inhibition assay | Inhibition of human DU-4475 cell growth in a cell viability assay, IC50=2.17137μM | SANGER | |||
| LNCaP-Clone-FGC | Growth inhibition assay | Inhibition of human LNCaP-Clone-FGC cell growth in a cell viability assay, IC50=2.18292μM | SANGER | |||
| C8166 | Growth inhibition assay | Inhibition of human C8166 cell growth in a cell viability assay, IC50=2.19604μM | SANGER | |||
| A172 | Growth inhibition assay | Inhibition of human A172 cell growth in a cell viability assay, IC50=2.21936μM | SANGER | |||
| LU-65 | Growth inhibition assay | Inhibition of human LU-65 cell growth in a cell viability assay, IC50=2.2225μM | SANGER | |||
| REH | Growth inhibition assay | Inhibition of human REH cell growth in a cell viability assay, IC50=2.25288μM | SANGER | |||
| SNG-M | Growth inhibition assay | Inhibition of human SNG-M cell growth in a cell viability assay, IC50=2.25741μM | SANGER | |||
| BFTC-905 | Growth inhibition assay | Inhibition of human BFTC-905 cell growth in a cell viability assay, IC50=2.29409μM | SANGER | |||
| KYSE-450 | Growth inhibition assay | Inhibition of human KYSE-450 cell growth in a cell viability assay, IC50=2.32175μM | SANGER | |||
| YT | Growth inhibition assay | Inhibition of human YT cell growth in a cell viability assay, IC50=2.33936μM | SANGER | |||
| COLO-205 | Growth inhibition assay | Inhibition of human COLO-205 cell growth in a cell viability assay, IC50=2.35082μM | SANGER | |||
| NCCIT | Growth inhibition assay | Inhibition of human NCCIT cell growth in a cell viability assay, IC50=2.35761μM | SANGER | |||
| ES1 | Growth inhibition assay | Inhibition of human ES1 cell growth in a cell viability assay, IC50=2.37637μM | SANGER | |||
| COR-L23 | Growth inhibition assay | Inhibition of human COR-L23 cell growth in a cell viability assay, IC50=2.37893μM | SANGER | |||
| PF-382 | Growth inhibition assay | Inhibition of human PF-382 cell growth in a cell viability assay, IC50=2.40589μM | SANGER | |||
| 8305C | Growth inhibition assay | Inhibition of human 8305C cell growth in a cell viability assay, IC50=2.41563μM | SANGER | |||
| TE-8 | Growth inhibition assay | Inhibition of human TE-8 cell growth in a cell viability assay, IC50=2.43077μM | SANGER | |||
| NCI-H460 | Growth inhibition assay | Inhibition of human NCI-H460 cell growth in a cell viability assay, IC50=2.46444μM | SANGER | |||
| BC-3 | Growth inhibition assay | Inhibition of human BC-3 cell growth in a cell viability assay, IC50=2.46857μM | SANGER | |||
| NH-12 | Growth inhibition assay | Inhibition of human NH-12 cell growth in a cell viability assay, IC50=2.48682μM | SANGER | |||
| KARPAS-422 | Growth inhibition assay | Inhibition of human KARPAS-422 cell growth in a cell viability assay, IC50=2.49504μM | SANGER | |||
| MC116 | Growth inhibition assay | Inhibition of human MC116 cell growth in a cell viability assay, IC50=2.51137μM | SANGER | |||
| C-33-A | Growth inhibition assay | Inhibition of human C-33-A cell growth in a cell viability assay, IC50=2.52669μM | SANGER | |||
| IGROV-1 | Growth inhibition assay | Inhibition of human IGROV-1 cell growth in a cell viability assay, IC50=2.53069μM | SANGER | |||
| MHH-PREB-1 | Growth inhibition assay | Inhibition of human MHH-PREB-1 cell growth in a cell viability assay, IC50=2.54832μM | SANGER | |||
| TUR | Growth inhibition assay | Inhibition of human TUR cell growth in a cell viability assay, IC50=2.56539μM | SANGER | |||
| LoVo | Growth inhibition assay | Inhibition of human LoVo cell growth in a cell viability assay, IC50=2.60537μM | SANGER | |||
| NCI-H1770 | Growth inhibition assay | Inhibition of human NCI-H1770 cell growth in a cell viability assay, IC50=2.61104μM | SANGER | |||
| YKG-1 | Growth inhibition assay | Inhibition of human YKG-1 cell growth in a cell viability assay, IC50=2.65153μM | SANGER | |||
| LOXIMVI | Growth inhibition assay | Inhibition of human LOXIMVI cell growth in a cell viability assay, IC50=2.65986μM | SANGER | |||
| KM12 | Growth inhibition assay | Inhibition of human KM12 cell growth in a cell viability assay, IC50=2.68746μM | SANGER | |||
| HCC1599 | Growth inhibition assay | Inhibition of human HCC1599 cell growth in a cell viability assay, IC50=2.69336μM | SANGER | |||
| HGC-27 | Growth inhibition assay | Inhibition of human HGC-27 cell growth in a cell viability assay, IC50=2.69567μM | SANGER | |||
| BE-13 | Growth inhibition assay | Inhibition of human BE-13 cell growth in a cell viability assay, IC50=2.70172μM | SANGER | |||
| IA-LM | Growth inhibition assay | Inhibition of human IA-LM cell growth in a cell viability assay, IC50=2.71158μM | SANGER | |||
| MEL-JUSO | Growth inhibition assay | Inhibition of human MEL-JUSO cell growth in a cell viability assay, IC50=2.73883μM | SANGER | |||
| RKO | Growth inhibition assay | Inhibition of human RKO cell growth in a cell viability assay, IC50=2.76509μM | SANGER | |||
| KS-1 | Growth inhibition assay | Inhibition of human KS-1 cell growth in a cell viability assay, IC50=2.78394μM | SANGER | |||
| NCI-H2087 | Growth inhibition assay | Inhibition of human NCI-H2087 cell growth in a cell viability assay, IC50=2.788μM | SANGER | |||
| HT-29 | Growth inhibition assay | Inhibition of human HT-29 cell growth in a cell viability assay, IC50=2.80856μM | SANGER | |||
| BHY | Growth inhibition assay | Inhibition of human BHY cell growth in a cell viability assay, IC50=2.81427μM | SANGER | |||
| BB30-HNC | Growth inhibition assay | Inhibition of human BB30-HNC cell growth in a cell viability assay, IC50=2.81504μM | SANGER | |||
| SF268 | Growth inhibition assay | Inhibition of human SF268 cell growth in a cell viability assay, IC50=2.82932μM | SANGER | |||
| GB-1 | Growth inhibition assay | Inhibition of human GB-1 cell growth in a cell viability assay, IC50=2.83283μM | SANGER | |||
| M059J | Growth inhibition assay | Inhibition of human M059J cell growth in a cell viability assay, IC50=2.84037μM | SANGER | |||
| BxPC-3 | Growth inhibition assay | Inhibition of human BxPC-3 cell growth in a cell viability assay, IC50=2.86491μM | SANGER | |||
| KYSE-510 | Growth inhibition assay | Inhibition of human KYSE-510 cell growth in a cell viability assay, IC50=2.86615μM | SANGER | |||
| KG-1 | Growth inhibition assay | Inhibition of human KG-1 cell growth in a cell viability assay, IC50=2.87472μM | SANGER | |||
| SNU-387 | Growth inhibition assay | Inhibition of human SNU-387 cell growth in a cell viability assay, IC50=2.89514μM | SANGER | |||
| COLO-320-HSR | Growth inhibition assay | Inhibition of human COLO-320-HSR cell growth in a cell viability assay, IC50=2.90092μM | SANGER | |||
| MRK-nu-1 | Growth inhibition assay | Inhibition of human MRK-nu-1 cell growth in a cell viability assay, IC50=2.90745μM | SANGER | |||
| L-363 | Growth inhibition assay | Inhibition of human L-363 cell growth in a cell viability assay, IC50=2.92677μM | SANGER | |||
| K5 | Growth inhibition assay | Inhibition of human K5 cell growth in a cell viability assay, IC50=2.93076μM | SANGER | |||
| Ramos-2G6-4C10 | Growth inhibition assay | Inhibition of human Ramos-2G6-4C10 cell growth in a cell viability assay, IC50=2.9464μM | SANGER | |||
| MEL-HO | Growth inhibition assay | Inhibition of human MEL-HO cell growth in a cell viability assay, IC50=2.95309μM | SANGER | |||
| CAL-51 | Growth inhibition assay | Inhibition of human CAL-51 cell growth in a cell viability assay, IC50=3.02334μM | SANGER | |||
| ES3 | Growth inhibition assay | Inhibition of human ES3 cell growth in a cell viability assay, IC50=3.02694μM | SANGER | |||
| ARH-77 | Growth inhibition assay | Inhibition of human ARH-77 cell growth in a cell viability assay, IC50=3.05574μM | SANGER | |||
| DEL | Growth inhibition assay | Inhibition of human DEL cell growth in a cell viability assay, IC50=3.07132μM | SANGER | |||
| LCLC-103H | Growth inhibition assay | Inhibition of human LCLC-103H cell growth in a cell viability assay, IC50=3.08304μM | SANGER | |||
| BCPAP | Growth inhibition assay | Inhibition of human BCPAP cell growth in a cell viability assay, IC50=3.17278μM | SANGER | |||
| HT-1080 | Growth inhibition assay | Inhibition of human HT-1080 cell growth in a cell viability assay, IC50=3.22505μM | SANGER | |||
| HLE | Growth inhibition assay | Inhibition of human HLE cell growth in a cell viability assay, IC50=3.23168μM | SANGER | |||
| T84 | Growth inhibition assay | Inhibition of human T84 cell growth in a cell viability assay, IC50=3.23358μM | SANGER | |||
| NB13 | Growth inhibition assay | Inhibition of human NB13 cell growth in a cell viability assay, IC50=3.24152μM | SANGER | |||
| HT-1376 | Growth inhibition assay | Inhibition of human HT-1376 cell growth in a cell viability assay, IC50=3.25385μM | SANGER | |||
| BB49-HNC | Growth inhibition assay | Inhibition of human BB49-HNC cell growth in a cell viability assay, IC50=3.30044μM | SANGER | |||
| SW620 | Growth inhibition assay | Inhibition of human SW620 cell growth in a cell viability assay, IC50=3.31159μM | SANGER | |||
| HOS | Growth inhibition assay | Inhibition of human HOS cell growth in a cell viability assay, IC50=3.32381μM | SANGER | |||
| CAL-85-1 | Growth inhibition assay | Inhibition of human CAL-85-1 cell growth in a cell viability assay, IC50=3.33331μM | SANGER | |||
| CGTH-W-1 | Growth inhibition assay | Inhibition of human CGTH-W-1 cell growth in a cell viability assay, IC50=3.36695μM | SANGER | |||
| GOTO | Growth inhibition assay | Inhibition of human GOTO cell growth in a cell viability assay, IC50=3.42269μM | SANGER | |||
| MZ2-MEL | Growth inhibition assay | Inhibition of human MZ2-MEL cell growth in a cell viability assay, IC50=3.47689μM | SANGER | |||
| RPMI-7951 | Growth inhibition assay | Inhibition of human RPMI-7951 cell growth in a cell viability assay, IC50=3.48317μM | SANGER | |||
| MZ1-PC | Growth inhibition assay | Inhibition of human MZ1-PC cell growth in a cell viability assay, IC50=3.48583μM | SANGER | |||
| NCI-H1355 | Growth inhibition assay | Inhibition of human NCI-H1355 cell growth in a cell viability assay, IC50=3.49073μM | SANGER | |||
| SW837 | Growth inhibition assay | Inhibition of human SW837 cell growth in a cell viability assay, IC50=3.54306μM | SANGER | |||
| CAL-39 | Growth inhibition assay | Inhibition of human CAL-39 cell growth in a cell viability assay, IC50=3.57017μM | SANGER | |||
| LOUCY | Growth inhibition assay | Inhibition of human LOUCY cell growth in a cell viability assay, IC50=3.6539μM | SANGER | |||
| GR-ST | Growth inhibition assay | Inhibition of human GR-ST cell growth in a cell viability assay, IC50=3.6986μM | SANGER | |||
| HT-144 | Growth inhibition assay | Inhibition of human HT-144 cell growth in a cell viability assay, IC50=3.71703μM | SANGER | |||
| KYSE-140 | Growth inhibition assay | Inhibition of human KYSE-140 cell growth in a cell viability assay, IC50=3.7452μM | SANGER | |||
| SJSA-1 | Growth inhibition assay | Inhibition of human SJSA-1 cell growth in a cell viability assay, IC50=3.77222μM | SANGER | |||
| LS-411N | Growth inhibition assay | Inhibition of human LS-411N cell growth in a cell viability assay, IC50=3.77806μM | SANGER | |||
| EHEB | Growth inhibition assay | Inhibition of human EHEB cell growth in a cell viability assay, IC50=3.79353μM | SANGER | |||
| Detroit562 | Growth inhibition assay | Inhibition of human Detroit562 cell growth in a cell viability assay, IC50=3.87838μM | SANGER | |||
| TE-441-T | Growth inhibition assay | Inhibition of human TE-441-T cell growth in a cell viability assay, IC50=3.95673μM | SANGER | |||
| HCT-116 | Growth inhibition assay | Inhibition of human HCT-116 cell growth in a cell viability assay, IC50=3.98142μM | SANGER | |||
| LP-1 | Growth inhibition assay | Inhibition of human LP-1 cell growth in a cell viability assay, IC50=4.02341μM | SANGER | |||
| NCI-H226 | Growth inhibition assay | Inhibition of human NCI-H226 cell growth in a cell viability assay, IC50=4.03207μM | SANGER | |||
| CHL-1 | Growth inhibition assay | Inhibition of human CHL-1 cell growth in a cell viability assay, IC50=4.046μM | SANGER | |||
| ESS-1 | Growth inhibition assay | Inhibition of human ESS-1 cell growth in a cell viability assay, IC50=4.0764μM | SANGER | |||
| OCUB-M | Growth inhibition assay | Inhibition of human OCUB-M cell growth in a cell viability assay, IC50=4.10756μM | SANGER | |||
| PANC-10-05 | Growth inhibition assay | Inhibition of human PANC-10-05 cell growth in a cell viability assay, IC50=4.14581μM | SANGER | |||
| NCI-H1651 | Growth inhibition assay | Inhibition of human NCI-H1651 cell growth in a cell viability assay, IC50=4.14794μM | SANGER | |||
| CAPAN-1 | Growth inhibition assay | Inhibition of human CAPAN-1 cell growth in a cell viability assay, IC50=4.15832μM | SANGER | |||
| COR-L279 | Growth inhibition assay | Inhibition of human COR-L279 cell growth in a cell viability assay, IC50=4.1999μM | SANGER | |||
| KU812 | Growth inhibition assay | Inhibition of human KU812 cell growth in a cell viability assay, IC50=4.24013μM | SANGER | |||
| G-361 | Growth inhibition assay | Inhibition of human G-361 cell growth in a cell viability assay, IC50=4.29726μM | SANGER | |||
| LU-134-A | Growth inhibition assay | Inhibition of human LU-134-A cell growth in a cell viability assay, IC50=4.32291μM | SANGER | |||
| NCI-H2228 | Growth inhibition assay | Inhibition of human NCI-H2228 cell growth in a cell viability assay, IC50=4.33895μM | SANGER | |||
| P12-ICHIKAWA | Growth inhibition assay | Inhibition of human P12-ICHIKAWA cell growth in a cell viability assay, IC50=4.36612μM | SANGER | |||
| NCI-H810 | Growth inhibition assay | Inhibition of human NCI-H810 cell growth in a cell viability assay, IC50=4.43547μM | SANGER | |||
| OCI-AML2 | Growth inhibition assay | Inhibition of human OCI-AML2 cell growth in a cell viability assay, IC50=4.48497μM | SANGER | |||
| MKN28 | Growth inhibition assay | Inhibition of human MKN28 cell growth in a cell viability assay, IC50=4.49326μM | SANGER | |||
| CAS-1 | Growth inhibition assay | Inhibition of human CAS-1 cell growth in a cell viability assay, IC50=4.50014μM | SANGER | |||
| HSC-2 | Growth inhibition assay | Inhibition of human HSC-2 cell growth in a cell viability assay, IC50=4.53165μM | SANGER | |||
| SK-NEP-1 | Growth inhibition assay | Inhibition of human SK-NEP-1 cell growth in a cell viability assay, IC50=4.53295μM | SANGER | |||
| Ca-Ski | Growth inhibition assay | Inhibition of human Ca-Ski cell growth in a cell viability assay, IC50=4.55409μM | SANGER | |||
| EW-18 | Growth inhibition assay | Inhibition of human EW-18 cell growth in a cell viability assay, IC50=4.57973μM | SANGER | |||
| CAL-27 | Growth inhibition assay | Inhibition of human CAL-27 cell growth in a cell viability assay, IC50=4.59437μM | SANGER | |||
| A427 | Growth inhibition assay | Inhibition of human A427 cell growth in a cell viability assay, IC50=4.60457μM | SANGER | |||
| IST-MEL1 | Growth inhibition assay | Inhibition of human IST-MEL1 cell growth in a cell viability assay, IC50=4.61122μM | SANGER | |||
| AN3-CA | Growth inhibition assay | Inhibition of human AN3-CA cell growth in a cell viability assay, IC50=4.66105μM | SANGER | |||
| RH-1 | Growth inhibition assay | Inhibition of human RH-1 cell growth in a cell viability assay, IC50=4.67159μM | SANGER | |||
| U-266 | Growth inhibition assay | Inhibition of human U-266 cell growth in a cell viability assay, IC50=4.70978μM | SANGER | |||
| NCI-H1734 | Growth inhibition assay | Inhibition of human NCI-H1734 cell growth in a cell viability assay, IC50=4.86317μM | SANGER | |||
| A101D | Growth inhibition assay | Inhibition of human A101D cell growth in a cell viability assay, IC50=4.87072μM | SANGER | |||
| EW-3 | Growth inhibition assay | Inhibition of human EW-3 cell growth in a cell viability assay, IC50=4.92537μM | SANGER | |||
| LB2241-RCC | Growth inhibition assay | Inhibition of human LB2241-RCC cell growth in a cell viability assay, IC50=4.92981μM | SANGER | |||
| NCI-H446 | Growth inhibition assay | Inhibition of human NCI-H446 cell growth in a cell viability assay, IC50=4.99284μM | SANGER | |||
| HCE-4 | Growth inhibition assay | Inhibition of human HCE-4 cell growth in a cell viability assay, IC50=5.02286μM | SANGER | |||
| SK-MEL-3 | Growth inhibition assay | Inhibition of human SK-MEL-3 cell growth in a cell viability assay, IC50=5.05667μM | SANGER | |||
| BB65-RCC | Growth inhibition assay | Inhibition of human BB65-RCC cell growth in a cell viability assay, IC50=5.1315μM | SANGER | |||
| ETK-1 | Growth inhibition assay | Inhibition of human ETK-1 cell growth in a cell viability assay, IC50=5.20947μM | SANGER | |||
| NCI-H526 | Growth inhibition assay | Inhibition of human NCI-H526 cell growth in a cell viability assay, IC50=5.27551μM | SANGER | |||
| MEG-01 | Growth inhibition assay | Inhibition of human MEG-01 cell growth in a cell viability assay, IC50=5.28014μM | SANGER | |||
| NB10 | Growth inhibition assay | Inhibition of human NB10 cell growth in a cell viability assay, IC50=5.29651μM | SANGER | |||
| NCI-H2170 | Growth inhibition assay | Inhibition of human NCI-H2170 cell growth in a cell viability assay, IC50=5.35475μM | SANGER | |||
| SK-PN-DW | Growth inhibition assay | Inhibition of human SK-PN-DW cell growth in a cell viability assay, IC50=5.37104μM | SANGER | |||
| MIA-PaCa-2 | Growth inhibition assay | Inhibition of human MIA-PaCa-2 cell growth in a cell viability assay, IC50=5.40002μM | SANGER | |||
| GI-1 | Growth inhibition assay | Inhibition of human GI-1 cell growth in a cell viability assay, IC50=5.4076μM | SANGER | |||
| Raji | Growth inhibition assay | Inhibition of human Raji cell growth in a cell viability assay, IC50=5.51421μM | SANGER | |||
| TE-5 | Growth inhibition assay | Inhibition of human TE-5 cell growth in a cell viability assay, IC50=5.53649μM | SANGER | |||
| HCC2998 | Growth inhibition assay | Inhibition of human HCC2998 cell growth in a cell viability assay, IC50=5.55443μM | SANGER | |||
| PANC-03-27 | Growth inhibition assay | Inhibition of human PANC-03-27 cell growth in a cell viability assay, IC50=5.55798μM | SANGER | |||
| VMRC-RCZ | Growth inhibition assay | Inhibition of human VMRC-RCZ cell growth in a cell viability assay, IC50=5.57737μM | SANGER | |||
| KYSE-180 | Growth inhibition assay | Inhibition of human KYSE-180 cell growth in a cell viability assay, IC50=5.61701μM | SANGER | |||
| NCI-H441 | Growth inhibition assay | Inhibition of human NCI-H441 cell growth in a cell viability assay, IC50=5.65336μM | SANGER | |||
| G-401 | Growth inhibition assay | Inhibition of human G-401 cell growth in a cell viability assay, IC50=5.74871μM | SANGER | |||
| MOLT-4 | Growth inhibition assay | Inhibition of human MOLT-4 cell growth in a cell viability assay, IC50=5.80892μM | SANGER | |||
| COLO-684 | Growth inhibition assay | Inhibition of human COLO-684 cell growth in a cell viability assay, IC50=5.84285μM | SANGER | |||
| A388 | Growth inhibition assay | Inhibition of human A388 cell growth in a cell viability assay, IC50=5.95373μM | SANGER | |||
| LC4-1 | Growth inhibition assay | Inhibition of human LC4-1 cell growth in a cell viability assay, IC50=5.97758μM | SANGER | |||
| ES8 | Growth inhibition assay | Inhibition of human ES8 cell growth in a cell viability assay, IC50=5.9826μM | SANGER | |||
| KYSE-150 | Growth inhibition assay | Inhibition of human KYSE-150 cell growth in a cell viability assay, IC50=6.04598μM | SANGER | |||
| IMR-5 | Growth inhibition assay | Inhibition of human IMR-5 cell growth in a cell viability assay, IC50=6.07759μM | SANGER | |||
| CAKI-1 | Growth inhibition assay | Inhibition of human CAKI-1 cell growth in a cell viability assay, IC50=6.10042μM | SANGER | |||
| NCI-H727 | Growth inhibition assay | Inhibition of human NCI-H727 cell growth in a cell viability assay, IC50=6.14571μM | SANGER | |||
| OPM-2 | Growth inhibition assay | Inhibition of human OPM-2 cell growth in a cell viability assay, IC50=6.15966μM | SANGER | |||
| HT | Growth inhibition assay | Inhibition of human HT cell growth in a cell viability assay, IC50=6.22363μM | SANGER | |||
| J-RT3-T3-5 | Growth inhibition assay | Inhibition of human J-RT3-T3-5 cell growth in a cell viability assay, IC50=6.23974μM | SANGER | |||
| SK-UT-1 | Growth inhibition assay | Inhibition of human SK-UT-1 cell growth in a cell viability assay, IC50=6.24479μM | SANGER | |||
| NCI-H2030 | Growth inhibition assay | Inhibition of human NCI-H2030 cell growth in a cell viability assay, IC50=6.24975μM | SANGER | |||
| CHP-212 | Growth inhibition assay | Inhibition of human CHP-212 cell growth in a cell viability assay, IC50=6.45324μM | SANGER | |||
| CHP-126 | Growth inhibition assay | Inhibition of human CHP-126 cell growth in a cell viability assay, IC50=6.50032μM | SANGER | |||
| C3A | Growth inhibition assay | Inhibition of human C3A cell growth in a cell viability assay, IC50=6.52544μM | SANGER | |||
| IGR-1 | Growth inhibition assay | Inhibition of human IGR-1 cell growth in a cell viability assay, IC50=6.53771μM | SANGER | |||
| RT4 | Growth inhibition assay | Inhibition of human RT4 cell growth in a cell viability assay, IC50=6.55973μM | SANGER | |||
| DMS-273 | Growth inhibition assay | Inhibition of human DMS-273 cell growth in a cell viability assay, IC50=6.60772μM | SANGER | |||
| DB | Growth inhibition assay | Inhibition of human DB cell growth in a cell viability assay, IC50=6.63611μM | SANGER | |||
| HCT-15 | Growth inhibition assay | Inhibition of human HCT-15 cell growth in a cell viability assay, IC50=6.64476μM | SANGER | |||
| U031 | Growth inhibition assay | Inhibition of human U031 cell growth in a cell viability assay, IC50=6.70596μM | SANGER | |||
| U-118-MG | Growth inhibition assay | Inhibition of human U-118-MG cell growth in a cell viability assay, IC50=6.78397μM | SANGER | |||
| RXF393 | Growth inhibition assay | Inhibition of human RXF393 cell growth in a cell viability assay, IC50=6.81231μM | SANGER | |||
| Calu-6 | Growth inhibition assay | Inhibition of human Calu-6 cell growth in a cell viability assay, IC50=6.86727μM | SANGER | |||
| G-402 | Growth inhibition assay | Inhibition of human G-402 cell growth in a cell viability assay, IC50=6.90229μM | SANGER | |||
| TK10 | Growth inhibition assay | Inhibition of human TK10 cell growth in a cell viability assay, IC50=6.96138μM | SANGER | |||
| TE-6 | Growth inhibition assay | Inhibition of human TE-6 cell growth in a cell viability assay, IC50=6.97183μM | SANGER | |||
| KP-N-YS | Growth inhibition assay | Inhibition of human KP-N-YS cell growth in a cell viability assay, IC50=6.99907μM | SANGER | |||
| AU565 | Growth inhibition assay | Inhibition of human AU565 cell growth in a cell viability assay, IC50=7.14606μM | SANGER | |||
| SIMA | Growth inhibition assay | Inhibition of human SIMA cell growth in a cell viability assay, IC50=7.17886μM | SANGER | |||
| PFSK-1 | Growth inhibition assay | Inhibition of human PFSK-1 cell growth in a cell viability assay, IC50=7.18927μM | SANGER | |||
| KYSE-410 | Growth inhibition assay | Inhibition of human KYSE-410 cell growth in a cell viability assay, IC50=7.22299μM | SANGER | |||
| CCF-STTG1 | Growth inhibition assay | Inhibition of human CCF-STTG1 cell growth in a cell viability assay, IC50=7.23949μM | SANGER | |||
| MKN1 | Growth inhibition assay | Inhibition of human MKN1 cell growth in a cell viability assay, IC50=7.29631μM | SANGER | |||
| 647-V | Growth inhibition assay | Inhibition of human 647-V cell growth in a cell viability assay, IC50=7.29741μM | SANGER | |||
| NOMO-1 | Growth inhibition assay | Inhibition of human NOMO-1 cell growth in a cell viability assay, IC50=7.37551μM | SANGER | |||
| KURAMOCHI | Growth inhibition assay | Inhibition of human KURAMOCHI cell growth in a cell viability assay, IC50=7.41109μM | SANGER | |||
| OVCAR-5 | Growth inhibition assay | Inhibition of human OVCAR-5 cell growth in a cell viability assay, IC50=7.41132μM | SANGER | |||
| UM-UC-3 | Growth inhibition assay | Inhibition of human UM-UC-3 cell growth in a cell viability assay, IC50=7.41425μM | SANGER | |||
| SCC-3 | Growth inhibition assay | Inhibition of human SCC-3 cell growth in a cell viability assay, IC50=7.50003μM | SANGER | |||
| NMC-G1 | Growth inhibition assay | Inhibition of human NMC-G1 cell growth in a cell viability assay, IC50=7.55058μM | SANGER | |||
| MS-1 | Growth inhibition assay | Inhibition of human MS-1 cell growth in a cell viability assay, IC50=7.70239μM | SANGER | |||
| SW48 | Growth inhibition assay | Inhibition of human SW48 cell growth in a cell viability assay, IC50=7.72775μM | SANGER | |||
| NEC8 | Growth inhibition assay | Inhibition of human NEC8 cell growth in a cell viability assay, IC50=7.76549μM | SANGER | |||
| LU-165 | Growth inhibition assay | Inhibition of human LU-165 cell growth in a cell viability assay, IC50=7.96706μM | SANGER | |||
| DU-145 | Growth inhibition assay | Inhibition of human DU-145 cell growth in a cell viability assay, IC50=7.9718μM | SANGER | |||
| IST-SL1 | Growth inhibition assay | Inhibition of human IST-SL1 cell growth in a cell viability assay, IC50=7.97673μM | SANGER | |||
| HuP-T4 | Growth inhibition assay | Inhibition of human HuP-T4 cell growth in a cell viability assay, IC50=7.9943μM | SANGER | |||
| DBTRG-05MG | Growth inhibition assay | Inhibition of human DBTRG-05MG cell growth in a cell viability assay, IC50=8.00301μM | SANGER | |||
| EB-3 | Growth inhibition assay | Inhibition of human EB-3 cell growth in a cell viability assay, IC50=8.05796μM | SANGER | |||
| K052 | Growth inhibition assay | Inhibition of human K052 cell growth in a cell viability assay, IC50=8.0798μM | SANGER | |||
| LS-1034 | Growth inhibition assay | Inhibition of human LS-1034 cell growth in a cell viability assay, IC50=8.2163μM | SANGER | |||
| CTB-1 | Growth inhibition assay | Inhibition of human CTB-1 cell growth in a cell viability assay, IC50=8.24089μM | SANGER | |||
| L-428 | Growth inhibition assay | Inhibition of human L-428 cell growth in a cell viability assay, IC50=8.29151μM | SANGER | |||
| NCI-H1648 | Growth inhibition assay | Inhibition of human NCI-H1648 cell growth in a cell viability assay, IC50=8.47578μM | SANGER | |||
| AGS | Growth inhibition assay | Inhibition of human AGS cell growth in a cell viability assay, IC50=8.50837μM | SANGER | |||
| NCI-H2347 | Growth inhibition assay | Inhibition of human NCI-H2347 cell growth in a cell viability assay, IC50=8.60378μM | SANGER | |||
| OVCAR-8 | Growth inhibition assay | Inhibition of human OVCAR-8 cell growth in a cell viability assay, IC50=8.60492μM | SANGER | |||
| NCI-H650 | Growth inhibition assay | Inhibition of human NCI-H650 cell growth in a cell viability assay, IC50=8.65528μM | SANGER | |||
| BV-173 | Growth inhibition assay | Inhibition of human BV-173 cell growth in a cell viability assay, IC50=8.66803μM | SANGER | |||
| SBC-1 | Growth inhibition assay | Inhibition of human SBC-1 cell growth in a cell viability assay, IC50=8.72336μM | SANGER | |||
| SF539 | Growth inhibition assay | Inhibition of human SF539 cell growth in a cell viability assay, IC50=8.79201μM | SANGER | |||
| SK-OV-3 | Growth inhibition assay | Inhibition of human SK-OV-3 cell growth in a cell viability assay, IC50=8.83193μM | SANGER | |||
| OE19 | Growth inhibition assay | Inhibition of human OE19 cell growth in a cell viability assay, IC50=8.90046μM | SANGER | |||
| HD-MY-Z | Growth inhibition assay | Inhibition of human HD-MY-Z cell growth in a cell viability assay, IC50=9.24971μM | SANGER | |||
| LU-99A | Growth inhibition assay | Inhibition of human LU-99A cell growth in a cell viability assay, IC50=9.34432μM | SANGER | |||
| NCI-H1304 | Growth inhibition assay | Inhibition of human NCI-H1304 cell growth in a cell viability assay, IC50=9.46093μM | SANGER | |||
| HL-60 | Growth inhibition assay | Inhibition of human HL-60 cell growth in a cell viability assay, IC50=9.50361μM | SANGER | |||
| EW-11 | Growth inhibition assay | Inhibition of human EW-11 cell growth in a cell viability assay, IC50=9.50376μM | SANGER | |||
| IM-9 | Growth inhibition assay | Inhibition of human IM-9 cell growth in a cell viability assay, IC50=9.66741μM | SANGER | |||
| 8-MG-BA | Growth inhibition assay | Inhibition of human 8-MG-BA cell growth in a cell viability assay, IC50=9.67802μM | SANGER | |||
| ES5 | Growth inhibition assay | Inhibition of human ES5 cell growth in a cell viability assay, IC50=9.7785μM | SANGER | |||
| NCI-H209 | Growth inhibition assay | Inhibition of human NCI-H209 cell growth in a cell viability assay, IC50=9.79721μM | SANGER | |||
| HCC1569 | Growth inhibition assay | Inhibition of human HCC1569 cell growth in a cell viability assay, IC50=9.81401μM | SANGER | |||
| NCI-H1573 | Growth inhibition assay | Inhibition of human NCI-H1573 cell growth in a cell viability assay, IC50=9.83855μM | SANGER | |||
| HCC2157 | Growth inhibition assay | Inhibition of human HCC2157 cell growth in a cell viability assay, IC50=9.88827μM | SANGER | |||
| NCI-H747 | Growth inhibition assay | Inhibition of human NCI-H747 cell growth in a cell viability assay, IC50=9.95861μM | SANGER | |||
| ONS-76 | Growth inhibition assay | Inhibition of human ONS-76 cell growth in a cell viability assay, IC50=9.96916μM | SANGER | |||
| NCI-H2009 | Growth inhibition assay | Inhibition of human NCI-H2009 cell growth in a cell viability assay, IC50=9.99172μM | SANGER | |||
| D-283MED | Growth inhibition assay | Inhibition of human D-283MED cell growth in a cell viability assay, IC50=10.0279μM | SANGER | |||
| HEC-1 | Growth inhibition assay | Inhibition of human HEC-1 cell growth in a cell viability assay, IC50=10.1758μM | SANGER | |||
| ABC-1 | Growth inhibition assay | Inhibition of human ABC-1 cell growth in a cell viability assay, IC50=10.2081μM | SANGER | |||
| HSC-4 | Growth inhibition assay | Inhibition of human HSC-4 cell growth in a cell viability assay, IC50=10.219μM | SANGER | |||
| SCC-4 | Growth inhibition assay | Inhibition of human SCC-4 cell growth in a cell viability assay, IC50=10.3242μM | SANGER | |||
| OE33 | Growth inhibition assay | Inhibition of human OE33 cell growth in a cell viability assay, IC50=10.3363μM | SANGER | |||
| TGW | Growth inhibition assay | Inhibition of human TGW cell growth in a cell viability assay, IC50=10.341μM | SANGER | |||
| KYSE-70 | Growth inhibition assay | Inhibition of human KYSE-70 cell growth in a cell viability assay, IC50=10.343μM | SANGER | |||
| NCI-H1963 | Growth inhibition assay | Inhibition of human NCI-H1963 cell growth in a cell viability assay, IC50=10.3515μM | SANGER | |||
| SF295 | Growth inhibition assay | Inhibition of human SF295 cell growth in a cell viability assay, IC50=10.3895μM | SANGER | |||
| BT-474 | Growth inhibition assay | Inhibition of human BT-474 cell growth in a cell viability assay, IC50=10.3997μM | SANGER | |||
| EM-2 | Growth inhibition assay | Inhibition of human EM-2 cell growth in a cell viability assay, IC50=10.5119μM | SANGER | |||
| PANC-08-13 | Growth inhibition assay | Inhibition of human PANC-08-13 cell growth in a cell viability assay, IC50=10.5427μM | SANGER | |||
| COLO-668 | Growth inhibition assay | Inhibition of human COLO-668 cell growth in a cell viability assay, IC50=10.7681μM | SANGER | |||
| NCI-H2196 | Growth inhibition assay | Inhibition of human NCI-H2196 cell growth in a cell viability assay, IC50=10.772μM | SANGER | |||
| HH | Growth inhibition assay | Inhibition of human HH cell growth in a cell viability assay, IC50=10.833μM | SANGER | |||
| SNU-449 | Growth inhibition assay | Inhibition of human SNU-449 cell growth in a cell viability assay, IC50=10.8474μM | SANGER | |||
| NCI-H28 | Growth inhibition assay | Inhibition of human NCI-H28 cell growth in a cell viability assay, IC50=10.9185μM | SANGER | |||
| NCI-H69 | Growth inhibition assay | Inhibition of human NCI-H69 cell growth in a cell viability assay, IC50=10.9708μM | SANGER | |||
| NB69 | Growth inhibition assay | Inhibition of human NB69 cell growth in a cell viability assay, IC50=10.9799μM | SANGER | |||
| RCM-1 | Growth inhibition assay | Inhibition of human RCM-1 cell growth in a cell viability assay, IC50=10.9966μM | SANGER | |||
| MHH-ES-1 | Growth inhibition assay | Inhibition of human MHH-ES-1 cell growth in a cell viability assay, IC50=11.02μM | SANGER | |||
| SHP-77 | Growth inhibition assay | Inhibition of human SHP-77 cell growth in a cell viability assay, IC50=11.0291μM | SANGER | |||
| HuCCT1 | Growth inhibition assay | Inhibition of human HuCCT1 cell growth in a cell viability assay, IC50=11.0329μM | SANGER | |||
| Saos-2 | Growth inhibition assay | Inhibition of human Saos-2 cell growth in a cell viability assay, IC50=11.0433μM | SANGER | |||
| LXF-289 | Growth inhibition assay | Inhibition of human LXF-289 cell growth in a cell viability assay, IC50=11.0849μM | SANGER | |||
| LS-123 | Growth inhibition assay | Inhibition of human LS-123 cell growth in a cell viability assay, IC50=11.2535μM | SANGER | |||
| HCC2218 | Growth inhibition assay | Inhibition of human HCC2218 cell growth in a cell viability assay, IC50=11.7063μM | SANGER | |||
| 5637 | Growth inhibition assay | Inhibition of human 5637 cell growth in a cell viability assay, IC50=11.8223μM | SANGER | |||
| Ca9-22 | Growth inhibition assay | Inhibition of human Ca9-22 cell growth in a cell viability assay, IC50=11.9261μM | SANGER | |||
| VA-ES-BJ | Growth inhibition assay | Inhibition of human VA-ES-BJ cell growth in a cell viability assay, IC50=12.1825μM | SANGER | |||
| A673 | Growth inhibition assay | Inhibition of human A673 cell growth in a cell viability assay, IC50=12.2268μM | SANGER | |||
| NCI-H292 | Growth inhibition assay | Inhibition of human NCI-H292 cell growth in a cell viability assay, IC50=12.4787μM | SANGER | |||
| NY | Growth inhibition assay | Inhibition of human NY cell growth in a cell viability assay, IC50=12.4944μM | SANGER | |||
| SK-N-AS | Growth inhibition assay | Inhibition of human SK-N-AS cell growth in a cell viability assay, IC50=12.727μM | SANGER | |||
| HuO-3N1 | Growth inhibition assay | Inhibition of human HuO-3N1 cell growth in a cell viability assay, IC50=13.1013μM | SANGER | |||
| AM-38 | Growth inhibition assay | Inhibition of human AM-38 cell growth in a cell viability assay, IC50=13.2146μM | SANGER | |||
| ML-2 | Growth inhibition assay | Inhibition of human ML-2 cell growth in a cell viability assay, IC50=13.2717μM | SANGER | |||
| SBC-5 | Growth inhibition assay | Inhibition of human SBC-5 cell growth in a cell viability assay, IC50=13.3058μM | SANGER | |||
| NCI-H2141 | Growth inhibition assay | Inhibition of human NCI-H2141 cell growth in a cell viability assay, IC50=13.4247μM | SANGER | |||
| A204 | Growth inhibition assay | Inhibition of human A204 cell growth in a cell viability assay, IC50=13.4388μM | SANGER | |||
| CAL-33 | Growth inhibition assay | Inhibition of human CAL-33 cell growth in a cell viability assay, IC50=13.5772μM | SANGER | |||
| HAL-01 | Growth inhibition assay | Inhibition of human HAL-01 cell growth in a cell viability assay, IC50=13.633μM | SANGER | |||
| COLO-679 | Growth inhibition assay | Inhibition of human COLO-679 cell growth in a cell viability assay, IC50=13.6566μM | SANGER | |||
| NCI-H889 | Growth inhibition assay | Inhibition of human NCI-H889 cell growth in a cell viability assay, IC50=13.715μM | SANGER | |||
| MN-60 | Growth inhibition assay | Inhibition of human MN-60 cell growth in a cell viability assay, IC50=13.7513μM | SANGER | |||
| MDA-MB-361 | Growth inhibition assay | Inhibition of human MDA-MB-361 cell growth in a cell viability assay, IC50=13.7543μM | SANGER | |||
| LB647-SCLC | Growth inhibition assay | Inhibition of human LB647-SCLC cell growth in a cell viability assay, IC50=14.0665μM | SANGER | |||
| GP5d | Growth inhibition assay | Inhibition of human GP5d cell growth in a cell viability assay, IC50=14.1627μM | SANGER | |||
| SK-N-DZ | Growth inhibition assay | Inhibition of human SK-N-DZ cell growth in a cell viability assay, IC50=14.1848μM | SANGER | |||
| DK-MG | Growth inhibition assay | Inhibition of human DK-MG cell growth in a cell viability assay, IC50=14.1855μM | SANGER | |||
| COLO-824 | Growth inhibition assay | Inhibition of human COLO-824 cell growth in a cell viability assay, IC50=14.2287μM | SANGER | |||
| NCI-H520 | Growth inhibition assay | Inhibition of human NCI-H520 cell growth in a cell viability assay, IC50=14.3819μM | SANGER | |||
| KP-N-YN | Growth inhibition assay | Inhibition of human KP-N-YN cell growth in a cell viability assay, IC50=14.6578μM | SANGER | |||
| LB771-HNC | Growth inhibition assay | Inhibition of human LB771-HNC cell growth in a cell viability assay, IC50=14.889μM | SANGER | |||
| SK-LMS-1 | Growth inhibition assay | Inhibition of human SK-LMS-1 cell growth in a cell viability assay, IC50=14.9452μM | SANGER | |||
| HCE-T | Growth inhibition assay | Inhibition of human HCE-T cell growth in a cell viability assay, IC50=15.0006μM | SANGER | |||
| U-87-MG | Growth inhibition assay | Inhibition of human U-87-MG cell growth in a cell viability assay, IC50=15.0328μM | SANGER | |||
| HCC1395 | Growth inhibition assay | Inhibition of human HCC1395 cell growth in a cell viability assay, IC50=15.0668μM | SANGER | |||
| H4 | Growth inhibition assay | Inhibition of human H4 cell growth in a cell viability assay, IC50=15.1266μM | SANGER | |||
| UMC-11 | Growth inhibition assay | Inhibition of human UMC-11 cell growth in a cell viability assay, IC50=15.2763μM | SANGER | |||
| THP-1 | Growth inhibition assay | Inhibition of human THP-1 cell growth in a cell viability assay, IC50=15.3277μM | SANGER | |||
| NCI-H82 | Growth inhibition assay | Inhibition of human NCI-H82 cell growth in a cell viability assay, IC50=15.4529μM | SANGER | |||
| COLO-680N | Growth inhibition assay | Inhibition of human COLO-680N cell growth in a cell viability assay, IC50=15.4673μM | SANGER | |||
| GI-ME-N | Growth inhibition assay | Inhibition of human GI-ME-N cell growth in a cell viability assay, IC50=15.6436μM | SANGER | |||
| OVCAR-4 | Growth inhibition assay | Inhibition of human OVCAR-4 cell growth in a cell viability assay, IC50=15.6753μM | SANGER | |||
| NCI-H2081 | Growth inhibition assay | Inhibition of human NCI-H2081 cell growth in a cell viability assay, IC50=15.8458μM | SANGER | |||
| NCI-H661 | Growth inhibition assay | Inhibition of human NCI-H661 cell growth in a cell viability assay, IC50=16.0221μM | SANGER | |||
| NCI-H1581 | Growth inhibition assay | Inhibition of human NCI-H1581 cell growth in a cell viability assay, IC50=16.0509μM | SANGER | |||
| SCC-15 | Growth inhibition assay | Inhibition of human SCC-15 cell growth in a cell viability assay, IC50=16.2537μM | SANGER | |||
| NB6 | Growth inhibition assay | Inhibition of human NB6 cell growth in a cell viability assay, IC50=16.2616μM | SANGER | |||
| HTC-C3 | Growth inhibition assay | Inhibition of human HTC-C3 cell growth in a cell viability assay, IC50=16.5031μM | SANGER | |||
| L-540 | Growth inhibition assay | Inhibition of human L-540 cell growth in a cell viability assay, IC50=16.619μM | SANGER | |||
| MHH-CALL-2 | Growth inhibition assay | Inhibition of human MHH-CALL-2 cell growth in a cell viability assay, IC50=16.6516μM | SANGER | |||
| NCI-H1092 | Growth inhibition assay | Inhibition of human NCI-H1092 cell growth in a cell viability assay, IC50=16.9599μM | SANGER | |||
| MFE-296 | Growth inhibition assay | Inhibition of human MFE-296 cell growth in a cell viability assay, IC50=16.9936μM | SANGER | |||
| HDLM-2 | Growth inhibition assay | Inhibition of human HDLM-2 cell growth in a cell viability assay, IC50=17.1559μM | SANGER | |||
| NCI-H2405 | Growth inhibition assay | Inhibition of human NCI-H2405 cell growth in a cell viability assay, IC50=17.6097μM | SANGER | |||
| HSC-3 | Growth inhibition assay | Inhibition of human HSC-3 cell growth in a cell viability assay, IC50=17.6307μM | SANGER | |||
| HOP-92 | Growth inhibition assay | Inhibition of human HOP-92 cell growth in a cell viability assay, IC50=17.6442μM | SANGER | |||
| SK-MEL-1 | Growth inhibition assay | Inhibition of human SK-MEL-1 cell growth in a cell viability assay, IC50=17.686μM | SANGER | |||
| NB5 | Growth inhibition assay | Inhibition of human NB5 cell growth in a cell viability assay, IC50=17.7495μM | SANGER | |||
| SK-CO-1 | Growth inhibition assay | Inhibition of human SK-CO-1 cell growth in a cell viability assay, IC50=17.8355μM | SANGER | |||
| LAMA-84 | Growth inhibition assay | Inhibition of human LAMA-84 cell growth in a cell viability assay, IC50=17.8808μM | SANGER | |||
| NCI-H510A | Growth inhibition assay | Inhibition of human NCI-H510A cell growth in a cell viability assay, IC50=18.0817μM | SANGER | |||
| SNU-423 | Growth inhibition assay | Inhibition of human SNU-423 cell growth in a cell viability assay, IC50=18.1141μM | SANGER | |||
| NCI-H596 | Growth inhibition assay | Inhibition of human NCI-H596 cell growth in a cell viability assay, IC50=18.1639μM | SANGER | |||
| LB2518-MEL | Growth inhibition assay | Inhibition of human LB2518-MEL cell growth in a cell viability assay, IC50=18.1656μM | SANGER | |||
| OAW-42 | Growth inhibition assay | Inhibition of human OAW-42 cell growth in a cell viability assay, IC50=18.4589μM | SANGER | |||
| RMG-I | Growth inhibition assay | Inhibition of human RMG-I cell growth in a cell viability assay, IC50=18.4596μM | SANGER | |||
| OVCAR-3 | Growth inhibition assay | Inhibition of human OVCAR-3 cell growth in a cell viability assay, IC50=18.4755μM | SANGER | |||
| NCI-H1755 | Growth inhibition assay | Inhibition of human NCI-H1755 cell growth in a cell viability assay, IC50=18.6462μM | SANGER | |||
| KMS-12-PE | Growth inhibition assay | Inhibition of human KMS-12-PE cell growth in a cell viability assay, IC50=18.6931μM | SANGER | |||
| COLO-741 | Growth inhibition assay | Inhibition of human COLO-741 cell growth in a cell viability assay, IC50=19.1772μM | SANGER | |||
| NCI-H1693 | Growth inhibition assay | Inhibition of human NCI-H1693 cell growth in a cell viability assay, IC50=19.2162μM | SANGER | |||
| no-11 | Growth inhibition assay | Inhibition of human no-11 cell growth in a cell viability assay, IC50=19.3835μM | SANGER | |||
| ATN-1 | Growth inhibition assay | Inhibition of human ATN-1 cell growth in a cell viability assay, IC50=19.7792μM | SANGER | |||
| ACN | Growth inhibition assay | Inhibition of human ACN cell growth in a cell viability assay, IC50=19.7965μM | SANGER | |||
| NCI-H1882 | Growth inhibition assay | Inhibition of human NCI-H1882 cell growth in a cell viability assay, IC50=19.9846μM | SANGER | |||
| COLO-800 | Growth inhibition assay | Inhibition of human COLO-800 cell growth in a cell viability assay, IC50=20.0569μM | SANGER | |||
| CPC-N | Growth inhibition assay | Inhibition of human CPC-N cell growth in a cell viability assay, IC50=20.1607μM | SANGER | |||
| LB373-MEL-D | Growth inhibition assay | Inhibition of human LB373-MEL-D cell growth in a cell viability assay, IC50=20.1859μM | SANGER | |||
| C2BBe1 | Growth inhibition assay | Inhibition of human C2BBe1 cell growth in a cell viability assay, IC50=20.658μM | SANGER | |||
| SK-MM-2 | Growth inhibition assay | Inhibition of human SK-MM-2 cell growth in a cell viability assay, IC50=21.0603μM | SANGER | |||
| NCI-H2052 | Growth inhibition assay | Inhibition of human NCI-H2052 cell growth in a cell viability assay, IC50=21.1765μM | SANGER | |||
| NCI-H1299 | Growth inhibition assay | Inhibition of human NCI-H1299 cell growth in a cell viability assay, IC50=21.2714μM | SANGER | |||
| NCI-H716 | Growth inhibition assay | Inhibition of human NCI-H716 cell growth in a cell viability assay, IC50=21.6758μM | SANGER | |||
| RO82-W-1 | Growth inhibition assay | Inhibition of human RO82-W-1 cell growth in a cell viability assay, IC50=22.0538μM | SANGER | |||
| HT-1197 | Growth inhibition assay | Inhibition of human HT-1197 cell growth in a cell viability assay, IC50=22.1812μM | SANGER | |||
| SF126 | Growth inhibition assay | Inhibition of human SF126 cell growth in a cell viability assay, IC50=22.2247μM | SANGER | |||
| HCC1187 | Growth inhibition assay | Inhibition of human HCC1187 cell growth in a cell viability assay, IC50=22.4063μM | SANGER | |||
| NUGC-3 | Growth inhibition assay | Inhibition of human NUGC-3 cell growth in a cell viability assay, IC50=22.5421μM | SANGER | |||
| NCI-H1436 | Growth inhibition assay | Inhibition of human NCI-H1436 cell growth in a cell viability assay, IC50=22.6406μM | SANGER | |||
| T-24 | Growth inhibition assay | Inhibition of human T-24 cell growth in a cell viability assay, IC50=22.7158μM | SANGER | |||
| TE-9 | Growth inhibition assay | Inhibition of human TE-9 cell growth in a cell viability assay, IC50=22.8553μM | SANGER | |||
| NCI-H1155 | Growth inhibition assay | Inhibition of human NCI-H1155 cell growth in a cell viability assay, IC50=22.9581μM | SANGER | |||
| SW962 | Growth inhibition assay | Inhibition of human SW962 cell growth in a cell viability assay, IC50=22.9585μM | SANGER | |||
| CAL-62 | Growth inhibition assay | Inhibition of human CAL-62 cell growth in a cell viability assay, IC50=24.0805μM | SANGER | |||
| RCC10RGB | Growth inhibition assay | Inhibition of human RCC10RGB cell growth in a cell viability assay, IC50=25.0059μM | SANGER | |||
| Calu-1 | Growth inhibition assay | Inhibition of human Calu-1 cell growth in a cell viability assay, IC50=25.209μM | SANGER | |||
| Daoy | Growth inhibition assay | Inhibition of human Daoy cell growth in a cell viability assay, IC50=25.4611μM | SANGER | |||
| NCI-H1618 | Growth inhibition assay | Inhibition of human NCI-H1618 cell growth in a cell viability assay, IC50=25.6125μM | SANGER | |||
| KALS-1 | Growth inhibition assay | Inhibition of human KALS-1 cell growth in a cell viability assay, IC50=25.6358μM | SANGER | |||
| SW948 | Growth inhibition assay | Inhibition of human SW948 cell growth in a cell viability assay, IC50=26.6228μM | SANGER | |||
| HuH-7 | Growth inhibition assay | Inhibition of human HuH-7 cell growth in a cell viability assay, IC50=26.765μM | SANGER | |||
| SNU-475 | Growth inhibition assay | Inhibition of human SNU-475 cell growth in a cell viability assay, IC50=26.9112μM | SANGER | |||
| TYK-nu | Growth inhibition assay | Inhibition of human TYK-nu cell growth in a cell viability assay, IC50=27.3462μM | SANGER | |||
| KNS-81-FD | Growth inhibition assay | Inhibition of human KNS-81-FD cell growth in a cell viability assay, IC50=27.5177μM | SANGER | |||
| CP50-MEL-B | Growth inhibition assay | Inhibition of human CP50-MEL-B cell growth in a cell viability assay, IC50=27.5746μM | SANGER | |||
| BFTC-909 | Growth inhibition assay | Inhibition of human BFTC-909 cell growth in a cell viability assay, IC50=27.5772μM | SANGER | |||
| C-4-II | Growth inhibition assay | Inhibition of human C-4-II cell growth in a cell viability assay, IC50=28.1344μM | SANGER | |||
| 23132-87 | Growth inhibition assay | Inhibition of human 23132-87 cell growth in a cell viability assay, IC50=28.1523μM | SANGER | |||
| LS-513 | Growth inhibition assay | Inhibition of human LS-513 cell growth in a cell viability assay, IC50=28.3421μM | SANGER | |||
| NCI-H1522 | Growth inhibition assay | Inhibition of human NCI-H1522 cell growth in a cell viability assay, IC50=28.8097μM | SANGER | |||
| OAW-28 | Growth inhibition assay | Inhibition of human OAW-28 cell growth in a cell viability assay, IC50=29.4404μM | SANGER | |||
| EFO-21 | Growth inhibition assay | Inhibition of human EFO-21 cell growth in a cell viability assay, IC50=29.4973μM | SANGER | |||
| HuP-T3 | Growth inhibition assay | Inhibition of human HuP-T3 cell growth in a cell viability assay, IC50=31.4825μM | SANGER | |||
| K-562 | Growth inhibition assay | Inhibition of human K-562 cell growth in a cell viability assay, IC50=31.5362μM | SANGER | |||
| NCI-H1694 | Growth inhibition assay | Inhibition of human NCI-H1694 cell growth in a cell viability assay, IC50=31.8337μM | SANGER | |||
| HCC1806 | Growth inhibition assay | Inhibition of human HCC1806 cell growth in a cell viability assay, IC50=32.6156μM | SANGER | |||
| Caov-3 | Growth inhibition assay | Inhibition of human Caov-3 cell growth in a cell viability assay, IC50=32.9306μM | SANGER | |||
| SK-N-FI | Growth inhibition assay | Inhibition of human SK-N-FI cell growth in a cell viability assay, IC50=34.005μM | SANGER | |||
| MKN7 | Growth inhibition assay | Inhibition of human MKN7 cell growth in a cell viability assay, IC50=34.3103μM | SANGER | |||
| NCI-H1650 | Growth inhibition assay | Inhibition of human NCI-H1650 cell growth in a cell viability assay, IC50=34.3281μM | SANGER | |||
| SCC-25 | Growth inhibition assay | Inhibition of human SCC-25 cell growth in a cell viability assay, IC50=34.4782μM | SANGER | |||
| 22RV1 | Growth inhibition assay | Inhibition of human 22RV1 cell growth in a cell viability assay, IC50=34.7965μM | SANGER | |||
| Calu-3 | Growth inhibition assay | Inhibition of human Calu-3 cell growth in a cell viability assay, IC50=34.9693μM | SANGER | |||
| RVH-421 | Growth inhibition assay | Inhibition of human RVH-421 cell growth in a cell viability assay, IC50=35.5404μM | SANGER | |||
| MMAC-SF | Growth inhibition assay | Inhibition of human MMAC-SF cell growth in a cell viability assay, IC50=36.1507μM | SANGER | |||
| A2058 | Growth inhibition assay | Inhibition of human A2058 cell growth in a cell viability assay, IC50=36.3986μM | SANGER | |||
| LK-2 | Growth inhibition assay | Inhibition of human LK-2 cell growth in a cell viability assay, IC50=36.4402μM | SANGER | |||
| EKVX | Growth inhibition assay | Inhibition of human EKVX cell growth in a cell viability assay, IC50=36.8979μM | SANGER | |||
| MKN45 | Growth inhibition assay | Inhibition of human MKN45 cell growth in a cell viability assay, IC50=37.914μM | SANGER | |||
| DG-75 | Growth inhibition assay | Inhibition of human DG-75 cell growth in a cell viability assay, IC50=38.3165μM | SANGER | |||
| NCI-H1417 | Growth inhibition assay | Inhibition of human NCI-H1417 cell growth in a cell viability assay, IC50=39.2032μM | SANGER | |||
| MDA-MB-175-VII | Growth inhibition assay | Inhibition of human MDA-MB-175-VII cell growth in a cell viability assay, IC50=39.206μM | SANGER | |||
| NCI-H1563 | Growth inhibition assay | Inhibition of human NCI-H1563 cell growth in a cell viability assay, IC50=39.7366μM | SANGER | |||
| NCI-H522 | Growth inhibition assay | Inhibition of human NCI-H522 cell growth in a cell viability assay, IC50=39.8603μM | SANGER | |||
| JVM-3 | Growth inhibition assay | Inhibition of human JVM-3 cell growth in a cell viability assay, IC50=40.2461μM | SANGER | |||
| T98G | Growth inhibition assay | Inhibition of human T98G cell growth in a cell viability assay, IC50=40.8281μM | SANGER | |||
| RPMI-8226 | Growth inhibition assay | Inhibition of human RPMI-8226 cell growth in a cell viability assay, IC50=40.8708μM | SANGER | |||
| SW1783 | Growth inhibition assay | Inhibition of human SW1783 cell growth in a cell viability assay, IC50=41.0964μM | SANGER | |||
| SW1573 | Growth inhibition assay | Inhibition of human SW1573 cell growth in a cell viability assay, IC50=41.2682μM | SANGER | |||
| SAS | Growth inhibition assay | Inhibition of human SAS cell growth in a cell viability assay, IC50=42.2375μM | SANGER | |||
| U251 | Growth inhibition assay | Inhibition of human U251 cell growth in a cell viability assay, IC50=42.252μM | SANGER | |||
| CAL-120 | Growth inhibition assay | Inhibition of human CAL-120 cell growth in a cell viability assay, IC50=44.7889μM | SANGER | |||
| CAL-148 | Growth inhibition assay | Inhibition of human CAL-148 cell growth in a cell viability assay, IC50=46.4174μM | SANGER | |||
| LU-139 | Growth inhibition assay | Inhibition of human LU-139 cell growth in a cell viability assay, IC50=46.6534μM | SANGER | |||
| KARPAS-299 | Growth inhibition assay | Inhibition of human KARPAS-299 cell growth in a cell viability assay, IC50=46.7965μM | SANGER | |||
| SH-4 | Growth inhibition assay | Inhibition of human SH-4 cell growth in a cell viability assay, IC50=47.4525μM | SANGER | |||
| SK-MEL-30 | Growth inhibition assay | Inhibition of human SK-MEL-30 cell growth in a cell viability assay, IC50=47.4553μM | SANGER | |||
| PC-14 | Growth inhibition assay | Inhibition of human PC-14 cell growth in a cell viability assay, IC50=48.4196μM | SANGER | |||
| KLE | Growth inhibition assay | Inhibition of human KLE cell growth in a cell viability assay, IC50=49.1388μM | SANGER | |||
| U937 | Function assay | Inhibition of SYK in human U937 cells assessed as reduction FcgammaR-mediated superoxide production, EC50=0.052μM | 22257213 | |||
| splenic B cells | Antiproliferative assay | Antiproliferative activity against mouse splenic B cells, EC50=0.058μM | 22257213 | |||
| Ramos B cells | Function assay | Inhibition of SYK in human Ramos B cells assessed as reduction in Ca2+ release, EC50=0.081μM | 22257213 | |||
| SJ-GBM2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 29435139 | |||
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 29435139 | |||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 29435139 | |||
| NB-EBc1 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 29435139 | |||
| Saos-2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 29435139 | |||
| NB1643 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 29435139 | |||
| LAN-5 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 29435139 | |||
| OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 29435139 | |||
| Rh41 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 29435139 | |||
| Click to View More Cell Line Experimental Data | ||||||
Biological Activity
| Description | BAY-61-3606 is a potent and selective inhibitor of Syk kinase (Ki = 7.5 nM). BAY-61-3606 induces cell cycle arrest and apoptosis. | ||
|---|---|---|---|
| Targets |
|
| In vitro | ||||
| In vitro | BAY 61-3606 is a highly selective inhibitor of Syk kinase. Other selected tyrosine kinases, Lyn, Fyn, Src, Itk, and Btk, are not inhibited by BAY 61-3606 in concentrations up to 4.7 μM. BAY 61-3606 is also found to inhibit B cell receptor (BCR)-mediated signaling[1]. Bay 61-3606 is a sensitizer of TRAIL-induced apoptosis. Mcl-1 downregulation by Bay 61-3606 are concentration- and time-dependent in MCF-7 cells. phosphorylation of Syk is reduced by Bay 61-3606 in MCF-7 and T47D cells. Downregulation of Mcl-1 by Bay 61-3606 is independent of Syk in breast cancer cells. Bay 61-3606 promotes the ubiquitin/proteasome-dependent degradation of the Mcl-1 protein in MCF-7 cells. Bay 61-3606 inhibits the phosphorylation of CDK9, RNA polymerase II, and Mcl-1 expression in MCF-7 cells. Bay 61-3606 inhibits CDK9 kinase activity with an in vitro IC50 of 37 nM[2]. |
|||
|---|---|---|---|---|
| Cell Research | Cell lines | MCF-7 cells | ||
| Concentrations | 2.5 μM or 5 μM | |||
| Incubation Time | 12 h or 24 h | |||
| Method | MCF-7 cells are exposed to TRAIL (indicated concentrations:0, 12.5, 25, 37.5 ng/ml) with or without Bay 61-3606 (2.5 μM) for 24 h; After exposure to the agents for 12 h, MCF-7 cells are subjected to immunocytochemistry using an active Bak antibody; Caspase activity is measured in MCF-7 cells exposed to Bay 61-3606 (5 μM) with or without TRAIL (50 ng/ml) for 24 h. |
|||
| In Vivo | ||
| In vivo | After 20 days of drug administration, the volume of the xenografted tumor was significantly (P <0.001) reduced the efficacy of Bay 61–3606 when administered in TRAIL combination[2]. Oral administration of BAY 61-3606 to rats significantly suppresses antigen-induced passive cutaneous anaphylactic reaction, bronchoconstriction, and bronchial edema at 3 mg/kg. Furthermore, BAY 61-3606 attenuates antigen-induced airway inflammation in rats[1]. |
|
|---|---|---|
Chemical Information & Solubility
| Molecular Weight | 463.32 | Formula | C20H18N6O3.2HCl |
| CAS No. | 648903-57-5 | SDF | Download BAY-61-3606 SDF |
| Smiles | COC1=C(C=C(C=C1)C2=CC3=NC=CN3C(=N2)NC4=C(C=CC=N4)C(=O)N)OC.Cl.Cl | ||
| Storage (From the date of receipt) | |||
|
In vitro |
DMSO : 14 mg/mL ( (30.21 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.) Water : Insoluble Ethanol : Insoluble |
Molecular Weight Calculator |
|
In vivo Add solvents to the product individually and in order. |
In vivo Formulation Calculator |
||||
Preparing Stock Solutions
Molarity Calculator
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
mg/kg
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
Tech Support
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
* Indicates a Required Field
Tags: buy BAY-61-3606 | BAY-61-3606 supplier | purchase BAY-61-3606 | BAY-61-3606 cost | BAY-61-3606 manufacturer | order BAY-61-3606 | BAY-61-3606 distributor
Products are for research use only. Not for human use. We do not sell to patients.
©Copyright 2013 Selleck Chemicals. All Rights Reserved.